PARIS, Oct. 13 /PRNewswire/ -- Cellectis bioresearch, a specialist in genome customization and subsidiary of Cellectis (Alternext: ALCLS), today announced that it has established a US subsidiary, Cellectis bioresearch Inc. Located at the Cambridge Innovation Center in Cambridge, Massachusetts, Cellectis bioresearch Inc. will be responsible for the US-wide promotion of Cellectis bioresearch products and services.
Cellectis bioresearch's portfolio today offers over 100 product references, fitting the major needs for genome customization of the life science community. These products include its cellular Genome Positioning System (cGPS®) and cGPS® Custom targeted integration kits, which enable the engineering of cell lines with optimized features for drug discovery, protein production and gene function studies.
Eric Merle will serve as Sales Director US. His strong experience in the research tool area in the United States will be a valuable asset in the launch of Cellectis bioresearch Inc.'s operations. Eric Merle will be in charge of recruiting and managing a dedicated team, covering the entire US market. He will report to Luc Selig, VP Sales & Marketing at Cellectis bioresearch.
"Cellectis bioresearch's goal is to make its genome customization products the gold standard for the life sciences community worldwide," explains Luc Selig. "The opening of our American subsidiary will provide us with a presence in the largest global Life Science market and allow us to be closer to our clients to better meet their needs."
Together with the recently announced partnership with the Canadian Life Science products distributor Cedarlane Inc., the creation of Cellectis bioresearch Inc. will establish a foothold for Cellectis bioresearch in the North American market.
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on meganucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional study. The kits can be purchased online from www.cellectis-bioresearch.com. More information on the website.
Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools - meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors. To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.
Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over 70 million euro in funding since inception.
More information at www.cellectis.com
Follow Cellectis on Twitter at www.twitter.com/cellectis
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.